FOR 2000-2004 US CASES
Rejection loss at 1 year was slightly lower but not significant, for US ED vs. BD in SPK (2.3 % vs. 3.1%) and PAK (6.6% vs. 9.0%). However, the ED 1 year rejection loss rate in PTA was significantly higher, 14.6% vs. 5.4% (p=0.03). By multivariate analysis, only PAK BD vs. ED had a higher HR risk for rejection loss (Table 5).
Table 5. Cox – regression for immunological pancreas graft failure (technically successful US DD primary pancreas transplants 1/1/2000 – 6/2004)
| Variables |
SPK
|
PAK
|
PTA
|
| |
p RR* |
p RR* |
p RR* |
| Large vs. Small Centers |
0.17 1.43 |
0.51 - |
0.15 3.08 |
| BD vs. ED |
0.71 - |
0.007 2.53 |
0.30 - |
| Donor Risk vs. None |
0.57 - |
0.12 1.60 |
0.28 - |
| HLA A: 2 vs. 1&0 MM |
0.005 2.08 |
0.11 1.61 |
0.86 - |
| HLA B: 2 vs. 1&0 MM |
0.62 - |
0.48 - |
0.09 2.17 |
Receipient Age
15-29 yrs vs. 30-44 yrs
≥45 yrs vs. 30-44 yrs |
0.46
0.06 0.58 |
0.48
0.03 0.45 |
0.32 -
0.04 0.33 |
| Deplet. AB Therapy |
0.32 - |
0.13 0.57 |
0.91 - |
| Nondepl. AB Therapy |
0.09 0.63 |
0.28 - |
0.89 - |
| TAC&MMF vs. Other |
0.75 - |
0.02 0.46 |
0.38 - |
| SIR vs. None |
0.16 0.51 |
0.17 0.36 |
- - |
Previous page / Next page / Index
Return to: Medical School : Academic Health Center : myU : U of M Home
